恒瑞医药(600276.SH)：SHR7280片药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of SHR7280 tablets [1] Group 1: Clinical Trial Results - The Phase III clinical trial (SHR7280-302) for SHR7280 tablets achieved its primary research endpoint as planned in November 2024 [1] - The study was a multicenter, randomized, double-blind, and non-inferiority trial involving 317 female infertility subjects, with the main researcher being Academician Qiao Jie from Peking University Third Hospital [1] - Results indicate that oral SHR7280 tablets have comparable clinical efficacy to subcutaneous injection of Acetate Ganirelix in controlled ovarian stimulation for assisted reproductive technology, effectively preventing early LH peak and premature ovulation, with overall good safety [1]